An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who ...

Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective analysis.

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer ...

Real-world treatment with liso-cel showed a broad spectrum of outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell ...

By addressing these issues, we can ensure that all patients, regardless of their socioeconomic status, have the opportunity ...

Meta: Blinatumomab plus chemotherapy, vs chemotherapy alone, significantly improved DFS rates and was well tolerated in ...

The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its ...

Cadonilimab plus platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.

According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer ...

The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.